Aktuellt
SENASTE
Redeye is encouraged to see the interbody spinal fusion clearance coming several months ahead of our estimated timeline. The news underpins our take on a hard launch in the field during early H2 2025, rather than the communicated late H2 2025. Until then, BONESUPPORT will focus on, and collect, documentation of its efficacy to build its (pre) clinical library. We expect the share to react positively on the news and trade upwards +10%. We reiterate our SEK256 base case (of which SEK42 refers to spinal fusion).
LÄS MER
